Medical management of ulcerative colitis

Digestive Diseases

Volumn 27, Issue 4, 2009, Pages 542-549

  Rogler, Gerhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Aminosalicylates; Inflammatory bowel disease; Medical management; Systemic therapy; Topical therapy; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; MESALAZINE; OLSALAZINE; STEROID; TACROLIMUS; TUMOR NECROSIS FACTOR INHIBITOR;

CECUM; CLOSTRIDIUM DIFFICILE; COLITIS; COLON MUCOSA; COLON RESECTION; CROHN DISEASE; DEFECATION HABIT; DIARRHEA; DISEASE ACTIVITY; DRUG SAFETY; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PATIENT SAFETY; PRIORITY JOURNAL; PROCTITIS; REMISSION; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ACUTE DISEASE; CHRONIC DISEASE; COLITIS, ULCERATIVE; HUMANS; MEGACOLON; REMISSION INDUCTION;

EID: 70449476259     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000233295     Document Type: Review

References (63)

1. Rao SS, Holdsworth CD, Read NW: Symptoms and stool patterns in patients with ulcerative colitis. Gut 1988; 29: 342-345.
2. Jones HW, Grogono J, Hoare AM: Surveillance in ulcerative colitis: burdens and benefit. Gut 1988; 29: 325-331.
3. Armitage EL, Aldhous MC, Anderson N, Drummond HE, Riemersma RA, Ghosh S, Satsangi J: Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology 2004; 127: 1051-1057.
4. Turunen P, Kolho KL, Auvinen A, Iltanen S, Huhtala H, Ashorn M: Incidence of inflammatory bowel disease in Finnish children, 1987-2003. Inflamm Bowel Dis 2006; 12: 677-683.
5. Vind I, Riis L, Jess T, Knudsen E, Pedersen N, Elkjaer M, Bak Andersen I, Wewer V, Nørregaard P, Moesgaard F, Bendtsen F, Munkholm P: Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101: 1274-1282.
6. Descos L, Andre F, Andre C, Gillon J, Landais P, Fermanian J: Assessment of appropriate laboratory measurements to reflect the degree of activity of ulcerative colitis. Digestion 1983; 28: 148-152.
7. Gionchetti P, Amadini C, Rizzello F, Venturi A, Campieri M: Treatment of mild to moderate ulcerative colitis and pouchitis. Aliment Pharmacol Ther 2002; 16(suppl 4):13-19.
8. Marshall JK, Irvine EJ: Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis. Gut 1997; 40: 775-781.
9. Campieri M, Gionchetti P, Belluzzi A, Brignola C, Migaldi M, Tabanelli GM, Bazzocchi G, Miglioli M, Barbara L: Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. Dig Dis Sci 1987; 32: 67S-70S.
10. Marshall JK, Irvine EJ: Rectal aminosalicylate therapy for distal ulcerative colitis: a meta-analysis. Aliment Pharmacol Ther 1995; 9: 293-300.
11. Campieri M, Gionchetti P, Belluzzi A, Brignola C, Tabanelli GM, Miglioli M, Barbara L: 5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis? J Clin Gastroenterol 1988; 10: 406-409.
12. Safdi M, DeMicco M, Sninsky C, Banks P, Wruble L, Deren J, Koval G, Nichols T, Targan S, Fleishman C, Wiita B: A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol 1997; 92: 1867-1871.
13. Regueiro M, Loftus EV Jr, Steinhart AH, Cohen RD: Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflamm Bowel Dis 2006; 12: 979-994. (Pubitemid 44498287)
14. Marshall JK, Irvine EJ: Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. Am J Gastroenterol 2000; 95: 1628-1636.
15. Sutherland L, MacDonald JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2003:CD000543.
16. Sutherland L, Macdonald JK: Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 2006:CD000543.
17. Mulder CJ, Tytgat GN, Wiltink EH, Houthoff HJ: Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. A prospective, randomized, double-blind trial. Scand J Gastroenterol 1988; 23: 1005-1008.
18. Mulder CJ, Fockens P, Meijer JW, van der Heide H, Wiltink EH, Tytgat GN: Beclomethasone dipropionate (3 mg) versus 5- aminosalicylic acid (2 g) versus the combination of both (3 mg/2 g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol 1996; 8: 549-553.
19. Lofberg R, Danielsson A, Suhr O, Nilsson A, Schioler R, Nyberg A, Hultcrantz R, Kollberg B, Gillberg R, Willen R, Persson T, Salde L: Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis. Gastroenterology 1996; 110: 1713-1718.
20. Katz JA: Medical and surgical management of severe colitis. Semin Gastrointest Dis 2000; 11: 18-32.
21. Baron JH, Connell AM, Kanaghinis TG, Lennard-Jones JE, Jones AF: Outpatient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J 1962; 2: 441-443.
22. Tremaine WJ, Schroeder KW, Harrison JM, Zinsmeister AR: A randomized, doubleblind, placebo-controlled trial of the oral mesalamine (5-ASA) preparation, Asacol, in the treatment of symptomatic Crohn's colitis and ileocolitis. J Clin Gastroenterol 1994; 19: 278-282.
23. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625-1629.
24. Kruis W, Kiudelis G, Racz I, Gorelov IA, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Bohm SK, Greinwald R, Muller R: Once-daily versus three-times-daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised non-inferiority trial. Gut 2009;58:233-240.
25. Kamm MA, Sandborn WJ, Gassull M, Schreiber S, Jackowski L, Butler T, Lyne A, Stephenson D, Palmen M, Joseph RE: Oncedaily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 2007; 132: 66-75.
26. Dignass AU, Bokemeyer B, Adamek HE, Mross MR, Vinter-Jensen L, Boerner N, Silvennoinen J, Tan TG, Oudkerk-Pool M, Stijnen T, Dietel P, Klugmann T, Veerman H: Maintenance therapy with once-daily 2 g mesalazine (Pentasa) treatment improves remission rates in subjects with ulcerative colitis compared to twice daily 1 g mesalazine: data from a randomised controlled trial. Gastroenterology 2008; 134:A494.
27. Truelove SC, Witts LJ: Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 2: 1041-1048.
28. D'Haens G, Lemmens L, Geboes K, Vandeputte L, Van Acker F, Mortelmans L, Peeters M, Vermeire S, Penninckx F, Nevens F, Hiele M, Rutgeerts P: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-1329.
29. Van Assche G, D'Haens G, Noman M, Vermeire S, Hiele M, Asnong K, Arts J, D'Hoore A, Penninckx F, Rutgeerts P: Randomized, double-blind comparison of 4 versus 2 mg/ kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-1031.
30. Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, Bala M, Johanns J, Olson A, Hanauer SB: The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 794-802.
31. Regueiro M, Curtis J, Plevy S: Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006; 40: 476-481.
32. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, Travers S, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Present D, Sands BE, Colombel JF: Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-2476. (Pubitemid 41770166)
33. Tsai HH, Punekar YS, Morris J, Fortun P: A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 1230-1239.
34. Ogata H, Matsui T, Nakamura M, Iida M, Takazoe M, Suzuki Y, Hibi T: A randomised dose finding study of oral tacrolimus (FK- 506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-1262.
35. Yamamoto S, Nakase H, Mikami S, Inoue S, Yoshino T, Takeda Y, Kasahara K, Ueno S, Uza N, Kitamura H, Tamaki H, Matsuura M, Inui K, Chiba T: Long-term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther 2008; 28: 589-597.
36. Hoffmann JC, Schwandner O, Bruch HP: Ulcerative colitis. Fulminant disease (in German). Z Gastroenterol 2004; 42: 1002-1006.
37. Minami M, Ohta M, Ohkura T, Ando T, Ohmiya N, Niwa Y, Goto H: Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 2007; 13: 754-760.
38. Kojima T, Watanabe T, Hata K, Shinozaki M, Yokoyama T, Nagawa H: Cytomegalovirus infection in ulcerative colitis. Scand J Gastroenterol 2006; 41: 706-711.
39. Kambham N, Vij R, Cartwright CA, Longacre T: Cytomegalovirus infection in steroid- refractory ulcerative colitis: a case-control study. Am J Surg Pathol 2004; 28: 365-373.
40. Cima RR, Pemberton JH: Surgical indications and procedures in ulcerative colitis. Curr Treat Options Gastroenterol 2004; 7: 181-190.
41. Meyers S, Lerer PK, Feuer EJ, Johnson JW, Janowitz HD: Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results of a prospective, randomized, doubleblind clinical trial. J Clin Gastroenterol 1987; 9: 50-54.
42. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-1845.
43. Cohen RD, Stein R, Hanauer SB: Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-1592.
44. Jarnerot G: Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology 2006; 130: 287.
45. Hanauer SB: Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology 2005; 129: 1358-1359.
46. Jarnerot G, Hertervig E, Friis-Liby I, Blomquist L, Karlen P, Granno C, Vilien M, Strom M, Danielsson A, Verbaan H, Hellstrom PM, Magnuson A, Curman B: Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-1811.
47. Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU: Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am J Gastroenterol 2006; 101: 1048-1056.
48. Aberra FN, Lewis JD, Hass D, Rombeau JL, Osborne B, Lichtenstein GR: Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125: 320-327.
49. Fernandez-Banares F, Bertran X, Esteve-Comas M, Cabre E, Menacho M, Humbert P, Planas R, Gassull MA: Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid- refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 2498-2499.
50. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V: The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37: 270-274.
51. Higgins RM, Bloom SL, Hopkin JM, Morris PJ: The risks and benefits of low-dose cotrimoxazole prophylaxis for Pneumocystis pneumonia in renal transplantation. Transplantation 1989; 47: 558-560.
52. Sands BE: Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut 2006; 55: 437-441.
53. Timmer A, McDonald J, Macdonald J: Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2007:CD000478.
54. Mantzaris GJ, Sfakianakis M, Archavlis E, Petraki K, Christidou A, Karagiannidis A, Triadaphyllou G: A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004; 99: 1122-1128.
55. Lopez-Sanroman A, Bermejo F, Carrera E, Garcia-Plaza A: Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis. Aliment Pharmacol Ther 2004; 20: 161-166.
56. Egan LJ, Sandborn WJ, Tremaine WJ, Leighton JA, Mays DC, Pike MG, Zinsmeister AR, Lipsky JJ: A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn's disease and ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1597-1604.
57. Sutherland L, Macdonald JK: Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2006:CD000544.
58. Orchard T, Probert CS, Keshav S: Review article: maintenance therapy in patients with ulcerative colitis. Aliment Pharmacol Ther 2006; 24(suppl 1):17-22.
59. Gionchetti P, Rizzello F, Morselli C, Tambasco R, Campieri M: Aminosalicylates for distal colitis. Aliment Pharmacol Ther 2006; 24(suppl 3):41-44.
60. Bergman R, Parkes M: Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther 2006; 23: 841-855.
61. Kane SV, Cohen RD, Aikens JE, Hanauer SB: Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. Am J Gastroenterol 2001; 96: 2929-2933.
62. Bohm SK, Kruis W: Probiotics: do they help to control intestinal inflammation? Ann NY Acad Sci 2006; 1072: 339-350.
63. Kruis W, Fric P, Pokrotnieks J, Lukas M, Fixa B, Kascak M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J: Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 2004; 53: 1617-1623.